Clene Nanomedicine Presents Blinded Interim Results from RESCUE-ALS Phase 2 Study at the 31st International Symposium on ALS/MND

NEXT STORY
Animal Wellness Action Executive Director Marty Irby Named one of The Hill’s Top Lobbyists for 2020
PREV STORY
Pfizer and BioNTech Announce Publication of Results from Landmark Phase 3 Trial of BNT162b2 COVID-19 Vaccine Candidate in The New England Journal of Medicine
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Innovation Pharmaceuticals Brilacidin Oral Mucositis Program Moving Forward Based Upon Positive Anchoring Phase 2 Results and Increased Brilacidin Franchise Value

BEVERLY, Mass., Dec. 18, 2017 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals, (OTCQB:IPIX) (“the Company”), a ...

author_avatar
NASDAQ Market News

New Data from Pivotal Phase 3 Study Investigating Lanadelumab as a Prophylactic Treatment for HAE to be Presented at 2018 AAAAI/WAO Joint Congress

New Data from Pivotal Phase 3 Study Investigating Lanadelumab as a Prophylactic Treatment for ...

author_avatar
NASDAQ Market News

Global Gene Therapy Market to 2020 with a Focus on the U.S.

Dublin, Nov. 08, 2018 (GLOBE NEWSWIRE) -- The "Global & US Gene Therapy Market ...

author_avatar
NASDAQ Market News